The Report of Three Rare Cases of the Niemann-pick Disease in Birjand, South Khorasan, Eastern Iran by NOROOZI ASL, Samaneh et al.
53Iran J Child Neurol. SUMMER  2017  Vol 11 No 3
Samaneh Noroozi ASl MD 1,
rahim VAkili  MD 2,
Nosrat GhAeMi MD 1,




The report of Three rare Cases of the Niemann-pick Disease in Birjand, South 
khorasan, eastern iran
1. Pediatrics Endocrinology 
Department, Mashhad University of 
Medical Sciences, Mashhad, Iran
2. Endocrinology Department, Mashhad 
University of Medical Sciences, 
Mashhad, Iran
Corresponding Author:
Noroozi Asl S. MD
Department of Pediatrics, Imam Reza 
Hospital, Mashhad University of 
Medical Sciences, Mashhad, Iran
Email: norouziasl@mums.ac.ir
Abstract
Niemann–Pick disease type C (NP-C) is a rare neurovisceral and irreversible 
disease leading to premature death and disabling neurological signs. This 
autosomal recessive disease with incidence rate of 1:120000 is caused by 
mutations in either the NPC1 or the NPC2 gene, which leads to accumulation 
of cholesterol in body tissues especially brain and progressive neurological 
symptoms. NP-C is characterized by nonspecific visceral, neurological 
and psychiatric manifestations in infants.  The neurological involvement is 
typically proceeded by systemic signs (cholestatic jaundice in the neonatal 
period or isolated spleno-or hepatosplenomegaly in infancy or childhood). 
Early detection of NPC is important so that therapy with miglustat can delay 
onset of neurological symptoms and prolong survival. We describe here three 
infants from Birjand, South Khorasan, eastern Iran in 2016 with splenomegaly 
and different neurological signs that diagnosis was confirmed by genetic 
study. In all of them, NPC-509 was pathologically increased. They also had 
an unreported homozygous mutation (c.1415T>C, p.Leu472Pro) in exon 9 of 
the NPC1 gene. We found unreported homozygous mutation in NPC gene. 
Knowing this mutation is significant to our people. Genotype-phenotype 
correlations for this specific mutation needs to be further studied.
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introduction 
Niemann-Pick disease type C (NP-C) is a rare, progressive genetic lysosomal lipid 
storage disease caused by mutations in the NPC1 or NPC2 gene and incidence 
rate of 1/120000. It is a highly heterogeneous disease, characterized by visceral, 
neurological and psychiatric manifestations that can be presented alone, or in 
specific or non-specific combinations (1). Moreover, age at onset and disease course 
is different. Very early-onset patients are often diagnosed based on isolated systemic 
manifestations, but patients most often present during childhood with one or more 
neurological manifestations such as abnormal saccadic eye movement disorders, 
cerebellar ataxia, learning problems, gelastic cataplexy and clumsiness (2).
Early diagnosis is essential so that therapy with miglustat can be initiated as soon 
as neurological symptoms appear in order to slow the progression of neurological 
damage.
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The second case is a three-yr-old girl, from Birjand, 
South Khorasan, and Iran. This patient is the cousin 
of the first case. She is the second child of non-related 
parents. The older sibling is healthy. The patient had 
birth weight of 2400 gr, height of 49 cm, and head 
circumference of 34 cm. By the age of nine months, 
she was developmentally normal and could sit and 
crawl. At the age of seven months, she was examined 
due to irritability and anemia pulse splenomegaly was 
diagnosed (ultrasonography showed spleen size of 108 
mm and normal echo). Since the age of nine months, 
she developmentally regressed and never obtained the 
capability of independent walking and talking. 
Liver function tests were normal and mild hypochromic 
microcytic anemia was detected in peripheral smear. 
The high-performance liquid chromatography of serum 
amino acids and MS/MS examinations, and enzyme 
assay for lipid storage disease was normal and in BMA, 
foamy cells were noted. In neurological examination, 
spasticity, platter dystopia, dysphagia, and clumsiness 
were observed. The patient also had history of frequent 
focal and generalized seizures controlled by anti-
epileptic drugs. In abdominal examination, splenomegaly 
extended to the pelvis and Vertical supranuclear gaze 
palsy was detected.
During the recent months, hypotonia after laughter 
and gelastic cataplexy were observed. Considering 
neurovascular symptoms, family history, and high NPC 
risk prediction scores, she was studied for NPC gene 
mutation and the diagnosis confirmed.
The third case is an 11-months-old boy from the same 
area, Birjand, South Khorasan, Iran. He is the first 
offspring of a consanguineous marriage. Due to mild 
hypochromic, microcytic anemia and splenomegaly 
were investigated. Liver function tests and enzyme 
assay for lipid storage disease was normal and foam 
cells were reported in BMA. He was developmentally 
age-appropriate. He could crawl and stand with help 
and speak 1-2 words. Neurological examination of the 
eye was normal and NPC risk prediction score was 
55. He underwent genetic analysis, as well. (Order no: 
62266939, Centogene Company)
In all the three cases, NPC-509 was pathologically 
increased; they also had an unreported homozygous 
mutation (c.1415T>C, p.Leu472Pro) in exon 9 of the 
Case report
The first case is a 3.75-yr old boy, referred to the Imam 
Reza Hospital, Pediatric Endocrinology and Metabolic 
Service, Mashhad, Iran in 2016. The patient is the first 
offspring of a first-cousin marriage from Birjand, South 
Khorasan, Iran, with birth weight of 2250 gr, 47 cm 
height, and head circumference of 34 cm. The patient 
had a history of neonatal jaundice from 40 days earlier.
Developmental milestones were delayed, the head 
holding was at five months, at nine months he was able 
to sit independently, and at the age of two years, he 
started to walk on feet. At six months, the patient was 
admitted to hospital due to gastroenteritis, and abdominal 
examination demonstrated splenomegaly. Cell blood 
count and liver transaminase function tests were normal 
and peripheral blood smear had no pathological finding. 
In fundoscopy, cherry red spot was not detected. For 
further investigation, bone marrow aspiration was 
performed, which exhibited foamy cells. Thereafter, 
enzyme assay was carried out, reporting normal activity 
of glucuronidase, galactokinase, and sphingomyelinase. 
There was no problem until 2.5 yr of age when he went 
to kindergarten. Speech and learning were acceptable; 
however, from the age of three, he started to suffer 
from ataxia and frequent falling, impaired speech, and 
dysphagia. At referral, spasticity, cerebellar dysfunction, 
dystonia, and splenomegaly were noted.
At the age of two, enzyme assay was re-performed, 
which was normal, but with probable diagnosis of 
Gaucher’s disease, enzyme replacement therapy was 
carried out for eight months. However, developmental 
regression trend was accelerated in the recent months 
and currently, he is not able to walk, sit, or swallow. 
He has no history of seizure or hearing impairment. 
Electroencephalogram revealed generalized sharp waves 
and in magnetic resonance imaging, sulcal widening and 
frontoparietal furrows were reported. Eye examination 
was abnormal and vertical supranuclear gaze palsy 
was detected. Moreover, in ultrasonography, spleen 
size was 41*122 with normal echo pattern and without 
hepatomegaly. Considering the combination of systemic 
and neurological symptoms and risk prediction score of 
higher than 70, NPC was suspected, accordingly, genetic 
analysis was performed and the diagnosis confirmed. 
(Order no: 62262135, Centogene Company)
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and strongest indicator of NPC, is seen in 66% of 
patients. VSGP accompanied with other signs such 
as splenomegaly and ataxia is highly predictive of 
NPC, observed in every two patients with neurological 
symptoms (1). Gelastic cataplexy is characterized by 
episodes of cataplexy, and is one of the most powerful 
predictive factors of NPC, observed in one of our 
patients.
BMA was carried out in each of the three patients 
due to splenomegaly, demonstrating foam cells. 
Moreover, enzyme assay showed normal activity of 
sphingomyelinase; in NPC, activity of this enzyme is 
normal despite A and B types. Based on systemic and 
neurological symptoms and through NPC risk prediction 
score, If NPC is strongly suspected, mutation of NPC-
1 and NPC-2 genes must be investigated, which is not 
only important for documentation, but also for prenatal 
diagnosis and carrier identification (4).
In all the three cases, NPC-509 was pathologically 
increased; they also had an unreported homozygous 
mutation (c.1415T>C, p.Leu472Pro) in exon 9 of the 
NPC1 gene.          
It is located in a weakly conserved nucleotide and 
highly conserved amino acid position, with moderate 
physicochemical differences between the amino acids 
leucine and proline. Software analysis by Polyphen -2, 
SIFT and Mutation Taster predict this variant is probably 
damaging. To date, this variant is not described in the 
Exome Aggregation Consortium, Exome Sequencing 
Project or the 100 Genomes Browser. The current 
number for identified NPC1 disease-causing mutations 
is near to 300.
In the NPC1 gene, one mutant allele, p.I1061T, is the 
most common (approximately 20%-25% of alleles in 
patients diagnosed in France or the United Kingdom) 
(1). In the homoallelic state, it correlates with a juvenile 
neurologic onset form of the disease.
The second common NPC1 mutation in Europe is 
p.P1007A. “The mutation p.G992W, typical of Nova-
Scotian patients is sporadically found (but rarely) in 
patients of another origin” (7). For NPC, it has been 
possible to make genotype- phenotype correlations that 
predict disease severity and allow more precise genetic 
counseling (8).
The genotype - phenotype studies in NP-C1 patients 
NPC1 gene. 
Discussion
NPC is a lipid storage disease with autosomal recessive 
inheritance of incidence rate of 1/120000. In this 
disease, the age of onset of clinical symptoms and 
rate of progression of neurological symptoms are 
highly variable and due to non-specific symptoms, its 
diagnosis is usually delayed until 5-6 yr after the onset 
of neurological symptoms (1). The minimizing delays 
in diagnosis for immediate initiation of miglustat are 
very important to hinder progression of neurological 
symptoms and improve treatment outcomes (3, 4).
The present study aimed to increase awareness and 
recognition of symptoms for early detection of NPC, 
especially in Iran, due to the high prevalence of 
consanguineous marriages. 
The true incidence of NPC is higher than the reported 
rates and these three cases are from Birjand, South 
Khorasan, with a population of 200000 people. We 
introduced three cases of NPC, two of which were 
diagnosed at the age of three yr and one case at one. 
All the three patients were studied due to systemic 
symptoms. In two cases, diagnosis was made after the 
neurological symptoms appeared, while for the other 
one, the disease was diagnosed before the onset of 
neurological symptoms. Two cases with neurological 
symptoms were considered in the late infantile (2-6 
yr) group. In 31% of NPC patients, the age of onset of 
neurological symptoms is in the same age range (5). 
The first and second cases were cousins and the third 
case shared the same family of origin. Considering the 
hereditary nature of NPC, having a sibling is a strong 
predictor of the disease and having a cousin with NPC is 
specific, but it is not very sensitive as only 3% of NPC 
patients had a cousin, involved (6).
Splenomegaly, which is a systemic sign of disease, 
appeared in all the three patients. In this age group, it 
might appear at birth or during the first months of life 
and can be the only clinical finding for many years. 
Isolated unexplained splenomegaly should always be 
the differential diagnosis for NPC and an indication for 
investigation of other clinical symptoms and repeated 
neurological evaluation (2).
Vertical supranuclear gaze palsy (VSGP), the hallmark 
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showed good correlation between nonsense or frameshift 
mutations and the most severe neurologic course (7). 
Patients often first present to general practitioners 
to nonspecific symptoms, the disease often remains 
undetected or diagnosis is made with many years delay 
(4). 
We should increase awareness about NPC among 
physicians to improve early diagnosis because early 
detection of NPC is essential so that therapy with 
miglustat (Zavesca, Actelion Pharmaceuticals Ltd) 
that acts as a competitive inhibitor of the enzyme, 
glucosylceramide synthase. Miglustat can delay onset of 
neurological symptoms and prolong survival (9). 
in Conclusion, we recommend that if NPC is suspected 
in an infant with systemic signs such as unexplained 
splenomegaly with or without hepatomegaly, prolonged 
neonatal cholestatic jaundice, hydrops fetalis and high 
score in NPC Suspicion Index tool, he/she should be 
referred to an NPC center for immediate genetic analysis. 
Documentation this mutation is specific to our people 
and genotype-phenotype correlations for this specific 
mutations needs to be further studies.
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